Loading company
enVVeno Medical Corp
NVNO · Nasdaq · ·
Next earnings: October 30, 2026
$8.89+1.7%Sep 29 close
- 1M
- -17.3%
- 6M
- -12.5%
- 1Y
- -72.0%
- 5Y
- -97.6%
NVNO · Nasdaq · ·
Next earnings: October 30, 2026
$8.89+1.7%Sep 29 close
enVVeno Medical Corp is scheduled to report next on October 30, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2019, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2019 | 3 months toDec 31, 2018 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $30.5K | -100.00% |
| Profit | -$3.6M | -$6.7M | +46.22% |
| Profit per share | -$0.23 | -$0.32 | +28.13% |
| Free Cash Flow | -$3.4M | -$3.9M | +12.19% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We have been working very closely with the FDA to ensure that the TAVVE study is structured to provide everything that the FDA wants to see in evaluating the safety and efficacy of enVVe and that we are in complete alignment,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from enVVeno Medical Corp’s Item 2.02 8-K filed April 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
enVVeno Medical Corp has no earnings call transcript available.